FLT3-mutated AML, with FLT3-ITD and FLT3-TKD mutations, leads to aggressive disease and poor outcomes, although FLT3 inhibitors have significantly improved survival rates despite resistance challenges [7,8]. Here, FLT3 is linked to acute myeloid leukemia.